Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy OfficerBusiness Wire • 09/22/25
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib CreamZacks Investment Research • 09/19/25
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic DermatitisBusiness Wire • 09/18/25
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025Business Wire • 09/17/25
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 CongressBusiness Wire • 09/10/25
Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% RallyInvestors Business Daily • 09/05/25
Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)Seeking Alpha • 09/04/25
Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis SuppurativaBusiness Wire • 09/03/25
Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/28/25
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources OfficerBusiness Wire • 08/25/25
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in BrazilGlobeNewsWire • 07/31/25
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product SalesZacks Investment Research • 07/29/25